WebOct 31, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … WebApr 11, 2024 · Dyne Therapeutics Stock Performance. NASDAQ DYN opened at $8.82 on Tuesday. The stock has a market cap of $496.90 million, a price-to-earnings ratio of -2.72 and a beta of 0.24.
Should You Add Dyne Therapeutics Inc (DYN) Stock to Your …
WebApr 11, 2024 · On average, analysts predict that Dyne Therapeutics will post -3.23 EPS for the current year. Insider Activity at Dyne Therapeutics. In related news, insider Jonathan Mcneill sold 10,000 shares of the company's stock in a transaction dated Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of … WebDyne Therapeutics 7,996 followers 1y Report this post Report Report. Back ... trump right to repair
Dyne Therapeutics launches with $50 million for oligonucleotide …
WebApr 11, 2024 · Ashburn, Virginia, United States, April 11, 2024 (GLOBE NEWSWIRE) -- Domo Tactical Communications (DTC), a CODAN company, has entered into a supply … WebJan 19, 2024 · Dyne Therapeutics, Inc. (NASDAQ: DYN) is a Waltham, Massachusetts based early clinical-stage biopharmaceutical concern focused on the development of oligonucleotide (small bits of RNA or DNA ... WebNov 2, 2024 · Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy August … philippines airasia check in online